Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis
Immunic, Inc. (NASDAQ: IMUX) announced positive results from the 50-week maintenance phase of its CALDOSE-1 trial for vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis. The 30 mg dose showed a statistically significant clinical remission rate of 61.5% versus 27.8% for the placebo (p=0.0358) and an endoscopic healing rate of 73.1% compared to 35.3% for placebo (p=0.0259). As a result, Immunic will concentrate resources on vidofludimus calcium and the IMU-856 programs while deprioritizing the izumerogant (IMU-935) program. Initial data for IMU-856 is expected this quarter.
- Clinical remission rate for 30 mg of vidofludimus calcium at 61.5%, significantly higher than placebo (27.8%).
- Endoscopic healing rate for 30 mg at 73.1% compared to placebo (35.3%).
- Statistically significant results with p-values of 0.0358 (clinical remission) and 0.0259 (endoscopic healing).
- No new safety signals were observed, with the drug well-tolerated.
- Deprioritization of izumerogant (IMU-935) may indicate challenges in its development.
- Phase 3 development of vidofludimus calcium in UC may not proceed without additional funding.
– 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo –
– 30 mg Once-Daily Dose of Vidofludimus Calcium Demonstrated Statistically Significant Rates of Clinical Remission (p=0.0358) and Endoscopic Healing (p=0.0259) at Week 50 –
– To Focus Resources on High Performing Vidofludimus Calcium and IMU-856 Programs, Immunic Decided to Deprioritize Izumerogant (IMU-935) Program –
– Conference Call and Webcast to be Held today,
Placebo | 10 mg | 30 mg | |
Clinical remission rate1 | (N=5/18) | (N=11/26) | (N=16/26) |
Steroid-free clinical remission rate | (N=5/18) | (N=10/26) | (N=16/26) |
Steroid-free clinical remission rate of patients who | (N=3) | (N=5) | (N=8) |
Endoscopic healing rate2 | (N=6/17) | (N=15/28) | (N=19/26) |
As shown above, data from the maintenance phase of CALDOSE-1 showed a dose-linear increase in clinical remission as compared to placebo at week 50. Moreover, an exploratory statistical analysis confirmed the 30 mg dose of vidofludimus calcium to be statistically superior (p=0.0358) in achieving clinical remission at week 50, with a
Consistent with prior data sets in other patient populations, administration of vidofludimus calcium in the maintenance phase of this trial was observed to be safe and well-tolerated. No new safety signals were observed. The incidence of treatment-emergent adverse events in both the 10 mg and 30 mg dose groups of vidofludimus calcium was comparable with placebo. There were no increased rates of liver events, liver enzyme elevations, renal events or adverse events of special interest, when compared to placebo, and no Hy's Law cases were observed.
"These impressive results from the maintenance phase of our CALDOSE-1 trial in patients with UC are extremely encouraging as they demonstrate statistically significant activity of vidofludimus calcium as compared to placebo. We believe this data compares favorably to available maintenance data for other UC drugs," commented
"Results from the maintenance phase of our CALDOSE-1 trial confirm previous observations in the induction phase that vidofludimus calcium provides a benefit regarding clinical remission, as compared to placebo, in UC patients not using concomitant corticosteroids," stated
The CALDOSE-1 trial of vidofludimus calcium in moderate-to-severe UC was a phase 2b, multicenter, randomized, double-blind, placebo-controlled, dose-finding study, including a blinded 10-week induction phase and a blinded 50-week maintenance phase. In the induction phase, 263 UC patients were enrolled at 78 study sites in
Update on Izumerogant (IMU-935) and IMU-856 Development Programs
In order to focus on the rapidly advancing vidofludimus calcium and IMU-856 programs, and considering the positive results from the CALDOSE-1 trial of vidofludimus calcium in UC, as well as the totality of available data for izumerogant, including changes in expected time to market and increased complexity of potential further development in this competitive field,
Regarding IMU-856, the company notes that the part C portion of the ongoing phase 1 clinical trial in celiac disease patients has been proceeding more quickly than anticipated, with initial data expected to become available in the current quarter.
Webcast Information
An archived replay of the webcast will be available approximately one hour after completion on
About Vidofludimus Calcium (IMU-838)
Vidofludimus calcium is a small molecule investigational drug in development as an oral next-generation treatment option for patients with multiple sclerosis and other chronic inflammatory and autoimmune diseases. The selective immune modulator is designed to inhibit the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase (DHODH). Vidofludimus calcium has been observed to act on activated T and B cells while leaving other immune cells largely unaffected and allows the immune system to stay functioning, e.g., in fighting infections. In previous trials, vidofludimus calcium did not show an increased rate of infections compared to placebo. In addition, DHODH inhibitors, such as vidofludimus calcium, are known to possess a host-based antiviral effect, which is independent with respect to specific virus proteins and their structure. Therefore, DHODH inhibition may be broadly applicable against multiple viruses. To date, vidofludimus calcium has been tested in more than 1,400 individuals and has shown an attractive pharmacokinetic, safety and tolerability profile. Vidofludimus calcium is not yet licensed or approved in any country.
About
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash, expected development, timing and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to
1 Clinical remission was defined as composite of patient-reported symptomatic remission (stool frequency Mayo subscore of 0 or 1, rectal bleeding Mayo score of 0) and modified Mayo endoscopy subscore of 0 or 1.
2 Endoscopic healing was defined as modified Mayo endoscopy subscore of 0 or 1.
Contact Information
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
+1 917 633 7790
immunic@rxir.com
US Media Contact
KOGS Communication
+1 617 974 8659
kaplan@kogspr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-reports-positive-data-from-maintenance-phase-of-phase-2-caldose-1-trial-of-vidofludimus-calcium-in-moderate-to-severe-ulcerative-colitis-301790538.html
SOURCE
FAQ
What were the results of the CALDOSE-1 trial for IMUX on April 5, 2023?
What is the focus of Immunic following the CALDOSE-1 trial results?
How does vidofludimus calcium compare to placebo based on the CALDOSE-1 trial?